Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;54(7):943-960.
doi: 10.1038/s41409-018-0378-z. Epub 2018 Nov 2.

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma

Parastoo B Dahi  1   2 , Hillard M Lazarus  3 , Craig S Sauter  4   5 , Sergio A Giralt  4   5
Affiliations
Review

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma

Parastoo B Dahi et al. Bone Marrow Transplant. 2019 Jul.

Abstract

High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards

Conflict of interest HML has been a consultant and promotional speaker for Seattle Genetics. The other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Schema for transplant and maintenance strategies in lymphoma. Transplant timing and maintenance options in lymphoma HL: hodgkin lymphoma, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma,MCL: mantle cell lymphoma, TCL: T-cell lymphoma HDT-AHCT: high-dose therapy and autologous stem cell transplantation
See this image and copyright information in PMC

References

    1. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Eng J Med. 1987;316:1493–8. - PubMed
    1. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multi-center study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93. - PMC - PubMed
    1. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–27. - PubMed
    1. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. 10.1200/JCO.2011.40.2719. - DOI - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Eng J Med. 1995;333:1540–5. - PubMed

Publication types